Results 291 to 300 of about 366,020 (324)

Adhering to Clinical Advice: The Level of Alignment of Care Processes With Global Bladder Guidelines in Veterans With Spinal Cord Injuries or Diseases

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background Guidelines contain recommendations for monitoring and care of neurogenic lower urinary tract dysfunction (NLUTD) in patients with spinal cord injury/disorder. Evidence on the level of adherence to these recommendations is limited.
John Lavelle, John Hornberger
wiley   +1 more source

Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration. [PDF]

Adv Ther
Freedland SJ, Ramaswamy K, Kavati A, Gao W, Razo JF, Cole M, Li B, Yang H, Guo T, Chen G, McKay RR.   +10 more
europepmc   +1 more source

Bladder Function and Safety of Vibegron in Men With Overactive Bladder Receiving Treatment for Benign Prostatic Hyperplasia: Outcomes From the Phase 3 Randomized Controlled COURAGE Trial

Neurourology and Urodynamics, EarlyView.
ABSTRACT Purpose Vibegron was associated with improvements in efficacy versus placebo and was well tolerated in men with overactive bladder (OAB) on pharmacotherapy for benign prostatic hyperplasia (BPH) in the COURAGE trial (NCT03902080). Additional safety, bladder function, and urodynamics data are provided.
Eric S. Rovner, Janet Owens‐Grillo, Elizabeth Thomas, Sender Herschorn, Kenneth M. Peters, David Staskin, Salim Mujais   +6 more
wiley   +1 more source

Prognostic Significance of Ultralow (UL) Prostate-Specific Antigen (PSA) in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Single Institution and Tertiary Cancer Center Experience. [PDF]

Medicina (Kaunas)
Suton P, Gregov V.
europepmc   +1 more source

Performance of Retrieval-Augmented Generation Large Language Models in Guideline-Concordant Prostate-Specific Antigen Testing: Comparative Study With Junior Clinicians.

J Med Internet Res
Tung JYM, Le Q, Yao J, Huang Y, Lim DYZ, Sng GGR, Lau RSE, Tan YG, Chen K, Tay KJ, Tan JH, Yuen JSP, Cheng CWS, Ho HSS.   +13 more
europepmc   +1 more source

Time to Prostate-Specific Antigen Failure as a Unique Prognosticator of Overall Survival in Biochemically Recurrent Prostate Cancer Patients Undergoing Radical Prostatectomy. [PDF]

Adv Urol
Shimabukuro T, Tokunaga T, Shimizu K, Fujii N, Kobayashi K, Hiroyoshi T, Hirata H, Shiraishi K.   +7 more
europepmc   +1 more source

Development of a Prostate-Specific Antigen Targeted Dual Drug Conjugate for Prostate Cancer Therapy. [PDF]

ACS Omega
Owoseni OB, Adekiya TA, Akinboye ES, Adesina SK.   +3 more
europepmc   +1 more source

Increased α2,3‐sialyl N‐glycosylated prostate‐specific membrane antigen (PSMA) in post‐DRE urine is associated with high grade group prostate cancer

Stephen Mackay, Ian O. Oduor, Tanya C. Burch, Brian P. Main, Dean A. Troyer, O. John Semmes, Julius O. Nyalwidhe   +6 more
openalex   +1 more source

Prostate-specific antigen density does not predict metastatic disease on PSMA-PET in high-risk prostate cancer patients with negative conventional imaging. [PDF]

Can Urol Assoc J
Kumar R, Lajkosz K, Metser U, Misurka J, Hiemstra J, Kreidstein J, Calicchia L, Silberman A, Finelli A, Fleshner NE, Hamilton RJ, Kulkarni GS, Zlotta A, Berlin A, Perlis N.   +14 more
europepmc   +1 more source

Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk.

JAMA Oncol
Tilki D, Chen MH, Wu J, Huland H, Graefen M, Trock BJ, Han M, D'Amico AV.   +7 more
europepmc   +1 more source